O-1Empresa com aprovações comprovadas
REG. 1336512
Associado de Pesquisa Pós-Doutorado - Biologia Química
St. Jude Medical, Cardiology Division, Inc.
✓ VERIFICADO · 19 green cards (PERM) aprovados nos últimos 12 mesesRegistros públicos do Departamento do Trabalho dos EUA (DOL).
- Local: Memphis, TN
- Área: Ciências & Pesquisa
- Visto provável: O-1
- Vaga vista pela última vez em 16/07/2026
Cargo de pós-doutorado em Memphis, TN; empresa com 19 aprovações PERM nos últimos 12 meses.
Cadastro grátis — o contato e o link oficial da vaga ficam no portal.
Descrição da vaga (original, em inglês)
A postdoc position is available in the lab of Taosheng Chen.
The Chen Lab ([link no portal] is seeking a Postdoctoral Research Associate to work in a multidisciplinary team to study the regulation of PXR and CAR, or CYP3A4 and CYP3A5, by characterizing novel chemical probes (i.e., small molecule inhibitors or degraders) in biochemical/biophysical, cellular and animal models.
Drug toxicity and resistance are the leading causes of therapeutic failures. The Chen Lab ([link no portal] studies: (1) the chemical regulation of nuclear xenobiotic receptors, (2) the mechanism of selective modulation of highly homologous drug-metabolizing enzymes. We are taking a hypothesis-driven and technology-enabled multidisciplinary approach to develop chemical probes, investigate biological mechanisms, and evaluate in vivo efficacy. In particular we use the promiscuous pregnane X receptor (PXR) and constitutive androstane receptor (CAR) as models. PXR and CAR transcriptionally regulate cytochrome P450 3A4 (CYP3A4) and CYP3A5—drug-metabolizing enzymes that metabolize more than 50% of clinical drugs, the dysregulation of which contributes to drug toxicity and drug resistance. We have developed the first selective PXR antagonist (Nat Commun 8:741, 2017; Nat Commun 15:4054, 2024); established that PXR and CAR form an unexpected heterodimer (Nucleic Acids Res 50:3254, 2022); revealed a mechanism that expands PXR’s ligand binding pocket to reduce ligand’s binding affinity (Proc Natl Acad Sci U S A. 120: e2217804120, 2023); and discovered the first CYP3A5-selective inhibitor and its structural basis (J Am Chem Soc 143:18467, 2021). Our goal is to understand nuclear receptor-regulated transcription networks, enzyme-drug interactions, and design therapeutic approaches to overcome drug resistance and toxicity in cellular and animal models.
The postdoctoral fellows will work in a multidisciplinary team to study the regulation of PXR and CAR, or CYP3A4 and CYP3A5, by characterizing novel chemical probes (i.e., small molecule inhibitors or degraders) in biochemical/biophysical, cellular and animal models. The fellows will contribute to or lead the effort of the multidisciplinary team (of biologists, medicinal chemists and structural biologists), organize and prepare manuscripts for publications. The fellows will be trained on manuscript and grant writing and encouraged (but not required) to prepare and submit grant proposals.
St. Jude is an Equal Opportunity Employer
No Search Firms
St. Jude Children's Research Hospital does not accept unsolicited assistance from search firms for employment opportunities. Please do not call or email. All resumes submitted by search firms to any employee or other representative at St. Jude via email, the internet or in any form and/or method without a valid written search agreement in place and approved by HR will result in no fee being paid in the event the candidate is hired by St. Jude.
Cadastro grátis — o contato e o link oficial da vaga ficam no portal.